ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

April 10, 2020

The pre-publication review and dispute process for the Open Payments 2019 program year has begun. Physicians and teaching hospitals may review and dispute any updated records attributed to them until May 15. The Centers for Medicare & Medicaid Services (CMS) will publish its Open Payments program year 2019 data and any updates to previous program years’ data in June 2020.

How to Review Data

April 10, 2020

Alexandria, VA – The American Society of Clinical Oncology (ASCO) today launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. The registry will collect both baseline and follow up data throughout the COVID-19 pandemic and into 2021.

April 10, 2020

The Department of Health and Human Services (HHS) announced that COVID-19 relief payments to hospitals, physicians, and other health care providers will begin arriving via direct deposit on April 10, 2020—to eligible providers throughout the U.S. health care system. 

April 10, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On April 10, 2020, the Food and Drug Administration approved selumetinib (KOSELUGO®, AstraZeneca) for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

April 9, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On April 8, 2020, the Food and Drug Administration approved encorafenib (BRAFTOVI®, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.

April 9, 2020

The American Society of Clinical Oncology (ASCO) today released a set of recommendations to support the oncology community as health care institutions across the United States face potentially difficult decisions around the allocation of scarce health care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is expected to demand more resources—including ventilators, critical and intensive care beds, and medications—than the U.S. or local health care systems can supply, and institutions will need to develop allocation decision policies as they provide care for a growing number of patients.

April 8, 2020

On April 14, the American Society of Clinical Oncology hosted the first session in its free “ASCO Global Webinar Series: Experiences and Lessons During the COVID-19 Pandemic.” The seminars are held each Tuesday from 8–9 a.m. (ET) and are available to view online at your convenience.

April 6, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

April 1, 2020

The American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) will host a weekly webinar series on caring for people with cancer during the COVID-19 pandemic.

March 31, 2020

To help ensure that health care providers have the resources necessary to care for patients during the COVID-19 pandemic, Congress and the Centers for Medicare & Medicaid Services (CMS) took action to provide direct financial support to providers who have been impacted by the emergency. The Coronavirus Aid, Relief, and Economic Security (CARES) Act and new guidance from CMS both contain provisions to provide financial support to qualified providers. 

March 31, 2020

The American Society of Clinical Oncology (ASCO) launched the Coronavirus (COVID-19) Community Forum on myConnection to facilitate discussion and peer-to-peer practice sharing among ASCO members as the oncology community works to continue to provide high-quality care to people with cancer during the COVID-19 pandemic.

March 30, 2020

On March 27, 2020, the Food and Drug Administration approved durvalumab (IMFINZI®, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

March 30, 2020

JCO Oncology Practice recently published an article written by the American Society of Clinical Oncology’s (ASCO) Ethics Committee focused on the causes of burnout in oncology as well as intervention methods. The article provides recommendations for individuals, organizations, and the Society to address burnout and ensure delivery of ethical and quality cancer care. 

March 30, 2020

In testimony submitted to Congress about the federal budget for FY 2021, ASCO thanked lawmakers for increasing funding for cancer research in FY2020 and urged them  to increase funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the Centers for Disease Control and Protection (CDC) in the year ahead.

March 27, 2020

Congress recently passed a third legislative package focused on stabilizing the United States economy and shoring up the health care system to ensure it is prepared to deal with the COVID-19 crisis. The bill includes key provisions that will impact the cancer care community, as well as patients with and survivors of cancer.

Pages